Grayscale Report: Tokenization is one of the many applications of public blockchain technology
The grayscale release research report states that tokenization refers to the registration of asset ownership on blockchain infrastructure. In a tokenized form, assets can benefit from the functions of the blockchain, including more efficient settlements and the ability to interact with smart contracts. In most cases, modern financial systems are already quite efficient, so tokenization itself may not immediately bring about efficiency improvements. Instead, we believe that the main benefits may come from integrating users, assets and applications onto a common global platform. From the perspective of crypto markets, although various assets might benefit from this trend towards tokenization, those with greatest potential are likely protocols capable of providing a universal global platform. Currently Grayscale Research believes Ethereum's blockchain is most likely to achieve this in future. Furthermore, according to the report,the first application for tokenization technology was stablecoins which tokenize one of simplest and most liquid assets: cash. Following stablecoins came gold as another widely adopted asset for tokenization.The latest wave of tokenisation has mainly focused on two different markets: US Treasury bonds and closely related assets along with credit products.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).